Home > Products > Novel inhibitors

CE3F4

  Cat. No.:  DC20336   Featured
Chemical Structure
143703-25-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
CE3F4 is a potent, noncompetitive EPAC1 inhibitor that blocks EPAC1-induced Rap1 activation both in cell-free systems and in intact cells and did not influence protein kinase A holoenzyme activity.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 143703-25-7
Chemical Name: CE3F4
Synonyms: CE3F4;CE3F4 NEW
SMILES: O=CN1C(C)CCC2=C(C(=C(C=C12)Br)F)Br
Formula: C11H10Br2FNO
M.Wt: 351.009604930878
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (Epac1), with IC50s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively.
Target: IC50: 10.7 μM (Epac1), 66 μM (Epac2(B))[1]
In Vitro: CE3F4 is a selective antagonist of Epac1, with IC50s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively. CE3F4 is more active on Epac1 than (S)-stereoisomer ((S)-CE3F4, IC50, 56 μM), but less active than (R)-CE3F4 (IC50, 5.8 μM). CE3F4 (50 μM) shows more inhibitory activities against GEF activity of Epac1, than that of Epac2(AB) or Epac2(B)[1]. CE3F4 reduces the exchange activity of Epac1 induced by 007, with IC50 of 23 ± 3 μM. CE3F4 (40 μM) specifically inhibits Epac1 guanine nucleotide exchange activity without interference with Rap1 activity or Epac1-Rap1 interaction. CE3F4 has no influence on PKA activity. CE3F4 (20 μM) inhibits Epac-induced Rap1 activation in living cultured HEK293 cells[2]. CE3F4 (20 μM) significantly inhibits the late phase of ERK activation stimulated by glucose in INS-1 cells[3].
Kinase Assay: To determine Epac1 exchange activity, 200 nM of purified GST-Rap1A preloaded with bGDP are incubated at 22°C in exchange buffer (50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 5 mM 1,4-dithioerythritol, 5% glycerol, 0.01% Nonidet P-40) in the presence of 100 nM purified GST-Epac1 or GST-Epac1-Cat; 20 μM unlabeled GDP; and defined concentrations of cAMP, cyclic nucleotide analogs, and test compounds (CE3F4). Experiments are performed in black 384-well plates in a final volume of 30 μL. bGDP fluorescence (excitation, 480 nm and emission, 535 nm) is measured using a multilabel plate reader[2].
Cell Assay: Cells are cultured overnight in 96-well black-walled plates at 37°C and 5% CO2, then washed twice in phosphate buffered saline. Cells are pre-incubated for two hours in glucose-free, modified KRBH supplemented with 0.05% fatty acid-free BSA at 37°C and 5% CO2. The pre-incubation buffer is decanted, and cells are stimulated with 18 mM glucose in KRBH. Cells are incubated with or without inhibitors (CE3F4) in modified KRBH for 30 min at 37°C and 5 % CO2 before glucose stimulation. The reactions are terminated at the indicated time points by decanting the treatments and fixing the cells with 4% formaldehyde. In experiments using pharmacological inhibitors, reactions are terminated 10 min after glucose stimulation is initiated. Total ERK and pERK is measured using the Phospho-ERK1 (T202/Y204) / ERK2 (T185/Y187) Cell-Based ELISA. Total ERK1/ERK2 is measured at 450 nm with excitation at 360 nm, and phosphorylated ERK1/ERK2 is measured at 600 nm with excitation at 540 nm, using a Synergy 4 Microplate Reader. The data are expressed as the ratio of pERK to total ERK then normalized and expressed as either fold over basal or % glucose response[3].
References: [1]. Courilleau D, et al. The (R)-enantiomer of CE3F4 is a preferential inhibitor of human exchange protein directly activated by cyclic AMP isoform 1 (Epac1). Biochem Biophys Res Commun. 2013 Oct 25;440(3):443-8. [2]. Courilleau D, et al. Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac. J Biol Chem. 2012 Dec 28;287(53):44192-202. [3]. Pratt EP, et al. Ca2+ influx through L-type Ca2+ channels and Ca2+-induced Ca2+ release regulate cAMP accumulation and Epac1-dependent ERK 1/2 activation in INS-1 cells. Mol Cell Endocrinol. 2016 Jan 5;419:60-71
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75202 Fosaprepitant free acid Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74557 PREX-in1 PREX-in1 is a specific small-molecule inhibitor of P-Rex1 and P-Rex2 Rac-GEF activity with IC50 of 4.5 uM (P-Rex1 DHPH Rac-GEF activity) in liposome-based GEF assay, inhibits P-Rex1 and P-Rex2 through their catalytic DH domain.
DC74555 GYS32661 GYS32661 (GYS 32661) is a potent Rac inhibitor capable of inhibiting both Rac1 and Rac1b, inhibited activated Rac1 with IC50 of 1.18 uM in in vitro pull-down assays.
DC74540 MTX-3937 MTX-3937 is a small-molecule inhibitor targeting Siglec-9 (Sialic acid-binding immunoglobulin-type lectin-9), a member of the Siglec family of immunomodulatory receptors. Siglec-9 is primarily expressed on immune cells, such as myeloid cells and natural killer (NK) cells, and plays a role in regulating immune responses by transmitting inhibitory signals through its intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs).
DC74539 L557-0155 L557-0155 is a small molecule inhibitor of VSIG-8, prevents VSIG-8 binding to VISTA, promotes cytokine production and cell proliferation in PBMCs and suppresses melanoma growth.
DC74528 K284 K284 is a selective small molecule inhibitor of chitinase 3 like1 (CHI3L1) with strong binding affinity (Kd=-9.7 kcal·mol-1), inhibits lung metastasis by blocking IL-13Rα2-mediated JNK-AP-1 signals.
DC74225 YB-537 YB-537 (YB537) is a potent, highly specific quinone reductase 2 (QR2) inhibitor with IC50 of 3 nM, shows no activity against QR1 (IC50>10 uM).
DC74224 XST-20 XST-20 is a small molecule that selectively targets the DNA-binding domain (DBD) of FOXM1, atranscription factor involved in cell cycle progression, proliferation, and cancer development. Witha surface plasmon resonance (SPR)-derived binding affinity (Kd) of 20 uM, XST-20 effectivelysuppresses FOXM1's transcriptional activities, making it a promising candidate for targetingFOXM1-driven cancers, such as ovarian cancer.
DC74223 X-Neu5Ac X-Neu5Ac (sodium) is a substrate for chromogenic assay of neuraminidase activity in bacterial expression systems; with a Km of 0.89 mM for neuraminidase.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia